Sir Walter Bodmer commenting on his appointment said:
"I have been highly impressed with the team of people that Christian has built at Oxford Genome Sciences. I am looking forward to working with them and bringing my expertise to help the company developing the personalised medicines that I believe are needed to dramatically improve the treatment of cancer."
About Oxford Genome Sciences
Oxford Genome Sciences (OGeS) is focused on the development of targeted medicines for oncology. The company uses OGAP(R), which it has developed into the world's largest cancer protein database, to discover novel clinically relevant drug targets and diagnostics.
OGeS' strategy is to use its unique and integrated OGAP(R) discovery platform in alliances with the world's leading antibody companies to develop OGeS targets into new antibody therapeutics and diagnostics that will deliver innovative and cost-effective medicines to fulfil unmet patient needs in the field of cancer. The company has signed a number of collaborations in the area of cancer, which are together designed to achieve OGeS' objective of developing novel personalised solutions to the management of cancer. Specifically in 2006, OGeS entered into partnerships with Medarex to discover, develop and commercialise new human antibody therapeutics for the treatment of cancers and with Biosite to develop a new diagnostic protein panel for relapsing colorectal cancer. In parallel, OGeS provides biomarker discovery and screening services to pharmaceutical and biotechnology companies.
OGeS, a privately held company, was formed in 2004 and is based near Oxford, UK.
Oxford Genome Anatomy Project (OGAP) holds the world's largest
proprietary collection of proteins represented by the database, which
contains over one million peptide sequences from 50 ti
|SOURCE Oxford Genome Sciences|
Copyright©2007 PR Newswire.
All rights reserved